Skip to main content

Table 2 Micro-RNAs as Non-invasive Biomarkers in Blood Samples

From: Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies

Cancer

Samples

Diagnostic miRs

Prognostic miRs

References

Head and Neck

Plasma

miR-184 (up)

 

[90]

Squamous cell carcinoma

Plasma

miR-24 (up)

 

[91]

 

Plasma

miR-31 (up)

 

[92]

 

Plasma

miR-181 (up)

miR-181 (up) correlated with poor survival, lymph-node metastasis, and vascular invasion

[93]

Breast cancer

Serum

 

miR-155 (up) in PR+ve patients

[68]

 

Plasma

miR-425*(up);

let-7d*(down)

 

[94]

 

Serum

miR-10b, -34a, -155 (up)

miR-10b, -34a, -155 (up) correlated with metastasis

[95]

 

Serum

miR -21, -106a, -155 (up); miR-126, -199a, -335 (down)

 

[96]

 

Whole blood

miR-195 (up)

miR-21, -10b (up) in ER -ve patients; let-7a (down) in lymph node +ve patients

[97]

 

Serum

 

miR-21 (up) correlated with visceral metastasis

[98]

Non-small-cell lung carcinoma

Pooled serum

miR-25, -223 (up)

 

[99]

 

Exosome from plasma

miR-17-3p, -21, -106a, -146, -155, -191, -192, -203, -205, -210, -212, -214 (up)

 

[58]

 

Pooled serum

 

miR-486, -30d (up); miR-1, -499 (down) associated with overall survival

[100]

 

Serum

miR-10b, -155 (up)

miR-10b (up) associated with lymph node metastasis

[101]

 

Vesicles of plasma samples

let-7d, let-7f, miR-223, -383, -192, -30e-5p, -301, -572, -20b, -345 (down)

let-7f, miR-30e-3p (up) associated with poor outcome

[59]

Gastrointestinal Cancers

Colorectal cancer

Plasma

miR-17-3p, -92 (up)

 

[102]

 

Plasma

miR-29a, -92a (up)

 

[103]

 

Plasma

miR-221 (up)

miR-221 (up) associated with poor overall survival

[104]

Esophageal

Serum

miR-10a, -22, -100, -148b, -223, -133a, -127-3p (up)

 

[105]

Gastric cancer

Serum

miR-1, -20a, -27a, -34, -423-5p (up)

miR-1, -20a, -27a, -34, -423-5p (up)

[106]

 

Plasma

miR-17-5p, -21, -106a, -106b (up); let-7a (down)

 

[107]

Hepatocellu-lar carcinoma

Serum

miR-500 (up)

 

[108]

 

Serum

miR-1, -25, -92a, -206, -375, -let-7f (up) (HBV-associated); miR-25, -375, and let-7f (up) (HCC detection)

 

[109]

 

Serum

miR-21, -122, -223 (up)

 

[110]

 

Serum

miR-122 (up)

 

[111]

 

Serum

miR-885-5p (up)

 

[112]

 

Serum

miR-16 (down) combined with AFP, AFP DCP increases specificity of HCC detection

 

[113]

Pancreatic cancer

Plasma

miR-21, -210, -155, -196a (up)

 

[63]

 

Plasma

miR-210 (up)

 

[62]

 

Plasma

miR-21 (up)

 

[60]

 

Serum

miR-21, -155, -196a (up)

miR-196a (up)

[61]

Ovarian cancer

Exosome from serum

miR-21, -141, -200a, -200c, -200b, -203, -205, -214 (up) correlated with stage

miR-21, -141, -200a, -200c, -200b, -203, -205, -214 (up) correlated with stage

[57]

 

Serum

miR-21, -92, -93, -126 -29a (up); miR-155, -127, -99b (down)

 

[64]

 

Whole blood

miR-30c1* (up); miR -342-3p, -181a*, -450b-5p (down)

 

[114]

Prostate cancer

Serum

miR-141 (up)

miR-100, -125b, -141, -143, -296 (up)

[54]

 

Serum

miR-16, -92a, -103, -107, -197, -34b, -328, -485-3p, -486-5p, -92b, -574-3p, -636, -640, -766, -885-5p (up)

 

[115]

 

Serum

miR-20b, -874, -1274a, -1207-5p, -93, -106a (up); miR- 223, -26b, -30c, -24 (down)

miR-24 (down) in metastatic cancers

[116]

 

Serum

miR-375, -141 (up)

miR-375, -141 (up)

[117]

 

Serum

miR-21 (up)

miR-21 (up) associated with resistant to docetaxel-based chemotherapy

[118]

 

Serum

miR-21, -141, -221 (up)

miR-21, -141, -221 (up)

[119]